المؤلفون: E. D., Ediboğlu, D., Solmaz, G., Kabadayı, S., Gücenmez, H., Cinaklı, E. O., Akat, M., Özmen, S., Akar

المصدر: ARP Rheumatology; Oct-Dec2023, Vol. 2 Issue 4, p322-329, 8p

مصطلحات موضوعية: NONSTEROIDAL anti-inflammatory agents, SPONDYLOARTHROPATHIES, TREATMENT of arthritis, C-reactive protein, DATA analysis

مستخلص: Objective: To evaluate non-steroidal anti-inflammatory drug (NSAID) use and Assessment in Spondyloarthritis International Society (ASAS)-NSAID scores in patients with axial spondyloarhritis (axSpA) in a longitudinal study. Methods: In total, 429 patients with axSpA (59% male; 64% with radiographic axSpA) were included in this study. Data regarding disease activity, C-reactive protein (CRP) levels, and NSAID use and dosage were collected at 0, 12, 24, and 52 weeks retrospectively. The relationship with NSAID use/ASAS-NSAID scores and other factors were tested using generalized estimating equations (GEE). Results: At baseline (week 0), 92.8% of patients in biologic disease-modifying anti-rheumatic drugs (bDMARDs) group and 82.1% of patients in conventional treatment group were being treated with NSAIDs. At baseline, the proportion (p=0.03) and the median (IQR) ASAS-NSAID scores were higher in bDMARDs group [100 (50-100) vs 50 (16.6-100); p<0.001]. During follow-up, NSAID use and ASAS-NSAID scores decreased significantly in patients treated with bDMARDs (p<0.001) and the reduction remained stable throughout the follow-up However, neither NSAID use (p=0.06) nor ASAS-NSAID scores changed in conventional treatment group (p=0.15). In bDMARDtreated patients, ASDAS-CRP and BASFI scores were independent determinants for NSAID use, and BASDAI and PGA were determinants for NSAID dosage. There was no independent significant predictor for ASAS-NSAID scores; PGA was the only significant predictor for NSAID use in the conventional treatment group. Conclusion: Biologic treatment was associated with low NSAID intake in patients with axSpA, and NSAID use was determined mainly by disease activity and partly by functional during bDMARD treatment. [ABSTRACT FROM AUTHOR]

: Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Rangiah, Selvandran¹ (AUTHOR), Govender, Indiran^2,3 (AUTHOR) indiran.govender@gmail.com, Badat, Zakariya⁴ (AUTHOR)

المصدر: South African Family Practice. 2020, Vol. 62 Issue 1, p1-5. 5p.

مصطلحات موضوعية: *TREATMENT of arthritis, *OSTEOARTHRITIS treatment, *RHEUMATOID arthritis treatment, *NONSTEROIDAL anti-inflammatory agents, *PRIMARY health care, *DISEASE management

مستخلص: Arthritis is a common condition seen frequently by family practitioners, and there are many types of arthritis. Management of arthritis depends largely on the specific type of arthritis that the patient suffers from. In this article, we will provide the primary care doctor with practical information for managing arthritis, focussing on the management of osteoarthritis and rheumatoid arthritis. [ABSTRACT FROM AUTHOR]

المؤلفون: Adam, Abdel Majid A.¹ majidadam@yahoo.com

المصدر: Applied Organometallic Chemistry. Feb2018, Vol. 32 Issue 2, p1-1. 11p.

مصطلحات موضوعية: *RHEUMATOID arthritis, *TREATMENT of arthritis, *NONSTEROIDAL anti-inflammatory agents, *TEMAZEPAM, *METAL complexes, *METAL ions, *STOICHIOMETRY, *CELL growth, *THERAPEUTICS

مستخلص: Recently, one of the most common conditions that manifests as joint and muscle inflammation is rheumatoid arthritis. One of the treatments for this arthritis includes non‐steroidal anti‐inflammatory drugs (NSAIDs) of the oxicam family, and the widest used drug in this family is tenoxicam (Tenox). In this study, the complexation properties of the drug Tenox with Ca(II), Sr(II) and Ba(II) ions in a (dichloromethane + water) binary solvent system are reported. The formed metal complexes were characterized structurally, thermally, and biologically. Tenox was found to act as a chelate monoanionic ligand towards all metal ions with complexation stoichiometry of 1:2 (Metal: Tenox) for Ca(II) and Sr(II) ions, and 1:1 for Ba(II) ions. The Tenox ligand behaves as a bidentate ligand when coordinated with Sr(II) or Ba(II) ions and as a tridentate ligand when coordinated with Ca(II) ions. The Sr(II) and Ba(II) complex of the Tenox ligand exhibited marked inhibitory effect on the cell growth of the C. albicans species. [ABSTRACT FROM AUTHOR]

المؤلفون: Asghar, Waheed¹, Aghazadeh-Habashi, Ali¹, Jamali, Fakhreddin¹ fjamali@ualberta.ca

المصدر: Inflammopharmacology. Oct2017, Vol. 25 Issue 5, p543-553. 11p.

مصطلحات موضوعية: *TREATMENT of arthritis, *NONSTEROIDAL anti-inflammatory agents, *ANTI-inflammatory agents, *RENIN-angiotensin system, *ALDOSTERONE, *HOMEOSTASIS, *THERAPEUTICS

مستخلص: A co-morbidity of inflammatory conditions is increased cardio-renal risks. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) which are used to treat pain and inflammation are also associated with increase in such risks. We hypothesized that inflammation and NSAIDs impose the cardio-renal risk through the activation of the renin-angiotensin-system (RAS), a regulating pathway of the renal and cardiovascular homeostasis. We investigated the effect of adjuvant arthritis and NSAIDs on the RAS. Western blotting and ELISA were used to measure the RAS components. Inflammation caused significant imbalances in the cardiac and renal angiotensin converting enzymes, their biologically active angiotensin peptides (AngII and Ang1-7) and the target proteins involved in the peptide-receptor binding (AngII type 1 and type 2, and Ang1-7 receptor, Mas) toward cardio-renal toxicity. However, 7 days treatment of arthritic animals with NSAIDs (rofecoxib, meloxicam, celecoxib and flurbiprofen) restored the constitutive balances, perhaps due to their anti-inflammatory properties. Inflammation exerts its cardio-renal effects by causing imbalance in the RAS. NSAIDs through their anti-inflammatory effect restore this imbalance. Thus, mechanisms other than imbalances in the RAS may be involved in the NSAIDs cardiotoxicity. [ABSTRACT FROM AUTHOR]

المصدر: Monthly Prescribing Reference. Jul2017, Vol. 33 Issue 6, p84-94. 11p.

مصطلحات موضوعية: *RHEUMATISM treatment, *TREATMENT of arthritis, *NONSTEROIDAL anti-inflammatory agents, *DRUG side effects, *DRUG dosage, *INTERLEUKIN-17, *PHOSPHODIESTERASE inhibitors

المؤلفون: Amodwala, Sejal¹, Kumar, Praveen¹, Thakkar, Hetal P.¹ hetal.thakkar-pharmacy@msubaroda.ac.in

المصدر: European Journal of Pharmaceutical Sciences. Jun2017, Vol. 104, p114-123. 10p.

مصطلحات موضوعية: *NONSTEROIDAL anti-inflammatory agents, *TREATMENT of arthritis, *POVIDONE, *MOLECULAR weights, *HISTOPATHOLOGY

مستخلص: Introduction The long term administration of Meloxicam for the management of arthritis, a chronic disorder, results in gastrointestinal disturbances leading to poor patient compliance. Considering the favorable molecular weight, therapeutic dose, biological half-life and log P value of meloxicam for transdermal delivery, its fast dissolving microneedle patch, with an ability to breach the stratum corneum and efficiently deliver the cargo to deeper skin layers, were developed. Methods Microneedle patch of low molecular weight polyvinyl alcohol and polyvinylpyrrolidone was prepared using Polydimethylsiloxane micromolds. The ratio of polyvinyl alcohol to polyvinyl pyrrolidone and solid content of matrix solution was optimized to achieve maximum needle strength. The optimized batch was extensively evaluated for in vitro dissolution, drug release, stability, ex vivo skin permeation/deposition, histopathology and in vivo pharmacodynamic study. Results The patch containing 9:1 polyvinyl alcohol to polyvinylpyrrolidone ratio with 50% solid content had shown maximum axial needle fracture force (0.9 N) suitable for penetrating the skin. The optimized batch was found to be fast dissolving and released almost 100% drug in 60 min following dissolution controlled kinetics. The formulation showed a significant drug deposition within skin (63.37%) and an improved transdermal flux (1.60 μg/cm 2 /h) with a 2.58 fold enhancement in permeation as compared to plain drug solution. The formulation showed a comparable anti-inflammatory activity in rats when compared to its existing approved marketed oral tablet. Histopathology and stability evaluations demonstrated acceptable safety and shelf-life of the developed formulation. Conclusion The successful verification of safety, efficacy and stability of microneedle patch advocated the suitability of the formulation for transdermal use. [ABSTRACT FROM AUTHOR]

المؤلفون: Qaseem, Amir¹ aqaseem@acponline.org, Harris, Russell P.², Forciea, Mary Ann³

المصدر: Annals of Internal Medicine. 1/3/2017, Vol. 166 Issue 1, p58-68. 13p. 1 Diagram, 2 Charts.

مصطلحات موضوعية: *GOUT treatment, *TREATMENT of arthritis, *RHEUMATISM treatment, *COLCHICINE, *NONSTEROIDAL anti-inflammatory agents

مستخلص: Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of gout. Methods: Using the ACP grading system, the committee based these recommendations on a systematic review of randomized, controlled trials; systematic reviews; and large observational studies published between January 2010 and March 2016. Clinical outcomes evaluated included pain, joint swelling and tenderness, activities of daily living, patient global assessment, recurrence, intermediate outcomes of serum urate levels, and harms. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with acute or recurrent gout. Recommendation 1: ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. (Grade: strong recommendation, high-quality evidence) Recommendation 2: ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute gout. (Grade: strong recommendation, moderate-quality evidence) Recommendation 3: ACP recommends against initiating long-term urate-lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. (Grade: strong recommendation, moderate-quality evidence) Recommendation 4: ACP recommends that clinicians discuss benefits, harms, costs, and individual preferences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks. (Grade: strong recommendation, moderate-quality evidence). [ABSTRACT FROM AUTHOR]

المؤلفون: Chevat, C.¹, Pena, B.M.², Al, M.J.³, Rutten, F.F.³

المصدر: PharmacoEconomics. Aug2001 Supplement 1, Vol. 19 Issue 8, p17-32. 16p. 4 Charts, 10 Graphs.

مصطلحات موضوعية: TREATMENT of arthritis, NONSTEROIDAL anti-inflammatory agents

مستخلص: Objective: The aim of the study was to perform an economic analysis of a new therapy in 11 countries (Australia, Belgium, Finland, France, Germany, Italy, The Netherlands, Spain, Sweden, Switzerland and the UK) to assess the cost of treating the gastrointestinal (GI) events associated with the use of nonsteroidal anti-inflammatory drugs in patients with osteoarthritis and rheumatoid arthritis. Methods: Estimates of GI event-related costs were based on the results of resource utilisation questionnaires. Resources required for the treatment and follow-up of GI events were identified and converted into costs from society and payer perspectives. Results: From the perspective of society, the total per-event cost of managing GI-related events varies from $US51 to $US772 for GI discomfort, from $US108 to $US1100 for anaemia, from $US145 to $US1200 for ulcer and from $US1923 to $US5473 for serious GI events requiring hospitalisation. From the payer perspective, the total per-event cost varies from $US47 to $US680 for GI discomfort, from $US144 to $US762 for anaemia, from $US229 to $US795 for ulcer and from $US1787 to $US6729 for serious GI events requiring hospitalisation. The total cost is driven by hospital expenses for those events requiring hospital admission. For GI discomfort, physician consultations are generally the cost driver, whereas for ulcer and anaemia, cost is primarily driven by the rate of endoscopy. Conclusions: Costs associated with nonsteroidal anti-inflammatory drug-related GI events differ significantly across countries as a result of variations in resources consumed and price/tariff policies. [ABSTRACT FROM AUTHOR]

: Copyright of PharmacoEconomics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Hunsche, E.¹, Chancellor, J.V.M.¹, Bruce, N.²

المصدر: PharmacoEconomics. Aug2001 Supplement 1, Vol. 19 Issue 8, p1-15. 15p. 2 Diagrams, 7 Charts, 3 Graphs.

مصطلحات موضوعية: TREATMENT of arthritis, NONSTEROIDAL anti-inflammatory agents

مستخلص: The purpose of this literature review is to summarise data available from publications describing the burden of osteoarthritis and rheumatoid arthritis in Europe, and to highlight gaps in the literature. On the basis of extensive literature research, the epidemiology of arthritis, its treatment costs, and iatrogenic costs related to nonsteroidal anti-inflammatory drug (NSAID) treatments are described, differentiating results by country. The review shows that, as well as having a significant impact on healthcare budgets, arthritis also affects patients and caregivers. For those countries where data were available, indirect costs were found to be of comparable magnitude to direct costs. Additionally, it was found that the iatrogenic costs related to the treatment of NSAID-induced adverse events are a significant component of the total costs of arthritis. The number of publications on the burden of arthritis in Europe is rather small in comparison with what is available for the US. Comparison of national results shows wide variations between countries, which may be partly due to discrepancies in the methodology applied to estimate the burden of arthritis, the cost items included in the analysis, and the data sources used to gather cost information. Additionally, comparing the burden of arthritis by country across Europe is difficult because of the variety of ways in which results are presented, e.g. on a per-patient basis, or for the whole population. To better understand the burden of illness of arthritis in Europe, not only is more research required, but the methodology to be applied in burden-of-illness analyses must also be standardised. [ABSTRACT FROM AUTHOR]

: Copyright of PharmacoEconomics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Schofield, Pat¹

المصدر: Practice Nurse. 3/28/2008, Vol. 35 Issue 6, p20-25. 4p. 1 Black and White Photograph, 1 Chart.

مصطلحات موضوعية: *NURSES, OSTEOARTHRITIS treatment, TREATMENT of arthritis, NURSING, NONSTEROIDAL anti-inflammatory agents, WEIGHT loss, ACETAMINOPHEN

مستخلص: The article discusses how nurses should manage pain ostearthritis in older people in whom the pain and disability may significantly diminish quality of life. The pain medications that can be given to osteoarthritis patients include paracetamol and nonsteroidal anti-inflammatory agents (NSAID). Weigt loss, and exercise are some of the non-pharmacological approaches of managing pain in osteoarthritis. The causes of osteoarthritis include obesity, genetics and injury.